

Amniotics granted Singapore patent for its amniotic fluid collection technology

Amniotics (publ) (Nasdaq Stockholm: AMNI) announced today that the The Singapore Patents Registry has approved a patent application for the company's amniotic fluid collection technology. This patent, no. 10201609919W, "Cells, methods and apparatuses for amniotic fluid collection and isolation of cells", provides Amniotics with protection for this technology in Singapore at least until 2034.

– Singapore is a well-known hub for biotechnology in the Asia-Pacific region and is thus important for Amniotics patent strategy of its neonatal stem cell platform. The amniotic fluid collection technology and our corresponding medical device is a cornerstone of our technology as it provides sterile cell material protected from ambient air whilst being completely safe for mother and child. We wish to thank our legal associates at Potter Clarkson for making this application successful, says Marcus Larsson, CEO, Amniotics AB.

For more information please contact

Marcus Larsson
CEO, Amniotics AB
Phone: +46 (0) 763 0840 91
Email: ml@amniotics.com

About Amniotics

Amniotics AB (publ) is a clinical stage biotech company, developing innovative therapies, based on amniotic fluid derived stem cells. The company develops therapies to treat diseases where effective treatments are currently lacking.

Amniotics has an established GMP-facility, approved and licensed by the Swedish Medical Products Agency. The company has capabilities as a Contract Development and Manufacturing Organization (CDMO) for other biotech companies.

Amniotics is headquartered in Lund, Sweden.

The company is listed at Nasdaq First North Growth Market in Stockholm. Amniotics Certified Adviser at First North is Redeye AB, e post: certifiedadviser@redeye.se.

Learn more at www.amniotics.com.

Attachments

[Amniotics granted Singapore patent for its amniotic fluid collection technology](#)